Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

323
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
323
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

335
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
335
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

284
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
284
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

256
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
256
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

279
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
279
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

337
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
337

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Linerixibat: First Approval.

Drugs·2026
Same author

Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.

Targeted oncology·2026
Same author

Taletrectinib: First Approval.

Drugs·2025
Same author

Trastuzumab Rezetecan: First Approval.

Drugs·2025
Same author

Correction to: Revakinagene Taroretcel: First Approval.

Molecular diagnosis & therapy·2025
Same author

Correction: Mirdametinib: First Approval.

Drugs·2025
Same journal

Molluscum Contagiosum Treatments in Children: A Systematic Review with Network Meta-Analysis.

Paediatric drugs·2026
Same journal

Real-World Systemic Treatment Patterns and Outcomes of Children With Severe Alopecia Areata: A French Nationwide Study (ESTAPED ohort).

Paediatric drugs·2026
Same journal

Epinephrine Underuse for Anaphylaxis in Infants and Toddlers: A Practical Review for Pediatricians.

Paediatric drugs·2026
Same journal

Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance.

Paediatric drugs·2026
Same journal

Discontinuing Colchicine in Pediatric Familial Mediterranean Fever: Real-Life Experience from a Long-Term Follow-Up Cohort.

Paediatric drugs·2026
Same journal

Sirolimus Therapy and Dyslipidemia in Neonates and Infants: A Retrospective Cohort and Pharmacovigilance Analysis.

Paediatric drugs·2026
查看所有相关文章

相关实验视频

Updated: Feb 17, 2026

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

3.0K

古塞尔库马布:儿童药物首次获得批准

Sheridan M Hoy1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. pdd@adis.com.

Paediatric drugs
|February 16, 2026
PubMed
概括
此摘要是机器生成的。

针对因特乐金-23的Guselkumab在美国和欧盟获得了针对斑块性牛皮和牛皮性关节炎的首个儿科批准. 这标志着治疗儿童免疫媒介炎症疾病的重要里程碑.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K

相关实验视频

Last Updated: Feb 17, 2026

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

3.0K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K

科学领域:

  • 免疫学 免疫学 免疫学
  • 皮肤病学 皮肤病学
  • 胃肠病学 胃肠病学

背景情况:

  • 古塞尔库马布向介素-23的p19亚单元,这是免疫介导炎症疾病中的关键细胞因子.
  • 它被批准用于患有斑块性牛皮,牛皮性关节炎,性结肠炎和克罗恩病的成年人.

研究的目的:

  • 总结古塞尔库马布的发展里程碑,导致其首次获得儿科批准.
  • 为了突出儿童斑块性牛皮和牛皮性关节炎的监管批准.

主要方法:

  • 对guselkumab的发展途径的审查.
  • 分析美国和欧盟的监管提交和批准.

主要成果:

  • 古塞尔库马布于2025年9月获得美国儿科批准,用于斑块性牛皮和牛皮关节炎 (6岁以上,≥40公斤).
  • 欧盟对中度至重度斑块性牛皮的儿科批准于2025年12月颁发 (年龄6岁以上).
  • 目前正在进行儿童克罗恩病和性结肠炎的III期试验.

结论:

  • 古塞尔库马布的开发已经成功地扩展到特定免疫媒介炎症疾病的儿科患者群体.
  • 这些批准代表了儿童治疗斑块牛皮和牛皮性关节炎的治疗选择的重大进步.